Friday, October 20, 2017

October 20th - Research Notes & Trade Blog



A Sleeper Stock With Tremendous Upside Potential. Could ALLM Be Our Next 
Ten-Bagger?  

We have been aggressive buyers of ALLM stock, based on the future potential of their CTS technology.



This is not a recommendation, or a solicitation to purchase or sell shares of  Alliance Bioenergy Plus Inc. (ALLM). Be sure to read our complete disclaimer  at www.altitradepartners.com. The opinions expressed herein are those of Altitrade Partners, and its principals, and should not be used as the basis for any decision to buy or sell securities. All investing involves risk. Do not rely solely on the opinions of others in making investment decisions. Please perform your own due diligence and invest responsibly. Altitrade Partners makes this blog available for informational purposes only. You should not follow our trading & investment strategies, as they are subject to change without notice. Altitrade Partners has not received any form of  compensation in connection with the publication of this report.

Thursday, October 19, 2017

October 19th - Research Notes & Trade Blog



Glucose Health, Inc. (GLUC) Announces Distribution Expansion To Include Amazon




This is not a recommendation, or a solicitation to purchase or sell shares of Glucose Health, Inc. (GLUC). Be sure to read our complete disclaimer  at www.altitradepartners.com. The opinions expressed herein are those of Altitrade Partners, and its principals, and should not be used as the basis for any decision to buy or sell securities. All investing involves risk. Do not rely solely on the opinions of others in making investment decisions. Please perform your own due diligence and invest responsibly. Altitrade Partners makes this blog available for informational purposes only. You should not follow our trading & investment strategies, as they are subject to change without notice. Altitrade Partners has not received any form of  compensation in connection with the publication of this report.


Tuesday, October 10, 2017

October 10th - Research Notes & Trade Blog


Glucose Health, Inc. (GLUC) Ramps Up Media Campaign To Include Fox Business Network, Bloomberg Television and The Oprah Winfrey Network


This past week saw two announcements from Glucose Health, Inc. (GLUC) indicating that the company is committed to spreading the word about its diabetic-friendly ice teas beyond its original targets.






The company announced that additional media segments will be appearing on both the Fox Business Network and Bloomberg Television as well as the popular show 20/20 on the Oprah Winfrey Network.



The big question is will all of this media coverage translate into increased sales of the company's products?

So far, there has been no indication by the company of the results of the campaign, as there was in the past

We will be more interested in looking for clues as to the effectiveness of the campaign in the coming weeks and months. Any meaningful increase in sales could be met with additional investor interest in the shares of GLUC.

This is not a recommendation, or a solicitation to purchase or sell shares of Glucose Health, Inc. (GLUC). Be sure to read our complete disclaimer  at www.altitradepartners.com. The opinions expressed herein are those of Altitrade Partners, and its principals, and should not be used as the basis for any decision to buy or sell securities. All investing involves risk. Do not rely solely on the opinions of others in making investment decisions. Please perform your own due diligence and invest responsibly. Altitrade Partners makes this blog available for informational purposes only. You should not follow our trading & investment strategies, as they are subject to change without notice. Altitrade Partners has not received any form of  compensation in connection with the publication of this report.

Thursday, September 28, 2017

September 28th - Research Notes & Trade Blog



More Eyes on Glucose Health, Inc. (GLUC) As Special Featured Product Report Expands Airing To Include 
CNBC's Mad Money With Jim Cramer




The airing of Glucose Health's Featured Product Report has begun on CNBC Shark Tank.

Front Montgomery, International Supermodel and Actress, is the "front" person for the company's new line of diabetic-friendly iced tea products.

As we wrote previously on our blog, back in April, the company has found a unexploited niche in addressing the growing diabetes epidemic that has become a major health issue here in the United States.

It seems that Shark Tank is not the only CNBC program that the special featured report will air on. It now appears that Jim Cramer's Mad Money viewers will also get exposure to the report, and along with it a bit of a mini-promotion of the fact that GLUC is a publicly traded company (see the 0:50 second mark of the video below).




According to the latest numbers from YouTube, the video has also been viewed over 52,000 times in the last two days on the YouTube website.

The two shows, Shark Tank and Mad Money, draw a lot of viewership and are among CNBC's most popular segments.

This is not a recommendation, or a solicitation to purchase or sell shares of Glucose Health, Inc. (GLUC). Be sure to read our complete disclaimer  at www.altitradepartners.com. The opinions expressed herein are those of Altitrade Partners, and its principals, and should not be used as the basis for any decision to buy or sell securities. All investing involves risk. Do not rely solely on the opinions of others in making investment decisions. Please perform your own due diligence and invest responsibly. Altitrade Partners makes this blog available for informational purposes only. You should not follow our trading & investment strategies, as they are subject to change without notice. Altitrade Partners has not received any form of  compensation in connection with the publication of this report.

Wednesday, September 27, 2017

September 27th - Research Notes & Trade Blog



NASDAQ Reports That Celsius Holdings, Inc. (CELH) Short Interest Climbs Another 41%, On Top Of The Previous Increase of 89% In The Prior Two-Week Reporting Period

Shares of Celsius Holdings, Inc. (CELH) seem to be drawing attention these days from short sellers who have driven the level of short interest as reported by NASDAQ to levels not seen since October 15, 2007.

In the latest period ending September 15, 2017, there were 350,568 shares that were reportedly sold short compared to 248,455 shares in the prior period. That is an increase of just over 41%.



This follows an increase of over 89% which was seen during the previous two-week reporting period.

Shares of CELH have now seen short interest rise some 223% since June 30, 2017, when the price of CELH shares stood at $4.25.

The last time short interest levels were this high was on October 15, 2007, when the number of shares short was at 345,469.

The all-time record for the number of shares short in CELH was for the reporting period ending July 25, 2007 when the number was 609,2341 shares.

The valuation thesis which we have presented, shows that shares of Celsius Holdings, Inc. are selling at extremely high levels based on most fundamental metrics.

The company's valuation (on a fully-diluted basis) is approximately $335 million at yesterday's closing price of $5.73.  

Putting an industry average 4X revenue number on the shares would require that CELH sales exceed $83 million for FY2017. They are currently at roughly $16 million for the first half of FY2017.

We believe that there's a lot of room for the share price to fall from here. It appears that a fair number of investors agree with that assessment.

This is not a recommendation, or a solicitation to purchase or sell shares of Celsius Holdings, Inc. ($CELH).  Be sure to read our complete disclaimer at www.altitradepartners.com. The opinions expressed herein are those of Altitrade Partners, and its principals, and should not be used as the basis for any decision to buy or sell securities. All investing involves risk. Do not rely solely on the opinions of others in making investment decisions. Please perform your own due diligence and invest responsibly. Altitrade Partners makes this blog available for informational purposes only. You should not follow our trading & investment strategies, as they are subject to change without notice.

  

Tuesday, September 26, 2017

September 26th - Research Notes & Trade Blog


Glucose Health Special Featured Product Report Now On-the-Air During Shark Tank on CNBC 





As was previously announced, fans of Shark Tank subscribing to Spectrum Cable in New York, Los Angeles, Dallas, Tampa-St. Petersburg, Charlotte and 75 more top TV markets across the country, will see this Glucose Health Special Featured Product Report during the weeks of September 25 through October 11.

This is not a recommendation, or a solicitation to purchase or sell shares of Glucose Health, Inc. (GLUC). Be sure to read our complete disclaimer at www.altitradepartners.com. The opinions expressed herein are those of Altitrade Partners, and its principals, and should not be used as the basis for any decision to buy or sell securities. All investing involves risk. Do not rely solely on the opinions of others in making investment decisions. Please perform your own due diligence and invest responsibly. Altitrade Partners makes this blog available for informational purposes only. You should not follow our trading & investment strategies, as they are subject to change without notice. Altitrade Partners has not received any form of  compensation in connection with the publication of this report.

Wednesday, September 20, 2017

September 20th - Research Notes & Trade Blog



Glucose Health, Inc. (GLUC) Marches To Another New High On Expanding Volume. Could There Be More Upside To Come?

As any stock market technician will tell you, a stock making new highs on increasing volume is a very good sign. 

It shows that not only are more buyers attracted to shares as volume expands, but that those buyers are willing to pay up to own shares as fewer and fewer sellers are willing to provide ample supply to meet the growing demand.


As the above chart shows, over the past two days GLUC has made consecutive new 52-week highs on increasing volume each day.

This oftentimes indicates that volume is the driving force to push shares higher. You may have heard the expression used in technical analysis that "volume always precedes price".

As long as new buyers are in abundance, and are willing to compete for price, eventually shares should reach new higher price levels. 

The level that we would keep an eye on is the old record high of around 0.50 cents set back in the summer of 2016. 

That area may provide some resistance, as those who bought at those record high prices will use the opportunity to get back to even after painfully holdings shares that they have been underwater on for almost 15 months. 

It is interesting to note on a 2-year chart that the  of that record high came on very limited volume. That made the move suspect, and, as one can clearly see on the chart, it did not last for very long.



The current run-up in price has strong volume behind it, which indicates that the move may be more sustainable.

The other thing to take into consideration, is that there are currently no shareholders who have purchased shares during the past 52 weeks that are showing a loss.

That kind of psychological advantage empowers shareholders who have profits, and makes them reluctant to release those profitable shares to new buyers.

This type of psychological advantage will persist until one of two things happen: First, the price reaches a level where the inclination for longs to take profits is just too great, and/or second, volume will begin to wane as fewer new buyers enter the arena to compete for the now over-priced shares. 

For now at least, we don't see either of these scenarios in the price/volume action of GLUC.

Could even higher prices be on the horizon? We think so.

This is not a recommendation, or a solicitation to purchase or sell shares of Glucose Health, Inc. (GLUC). Be sure to read our complete disclaimer at www.altitradepartners.com. The opinions expressed herein are those of Altitrade Partners, and its principals, and should not be used as the basis for any decision to buy or sell securities. All investing involves risk. Do not rely solely on the opinions of others in making investment decisions. Please perform your own due diligence and invest responsibly. Altitrade Partners makes this blog available for informational purposes only. You should not follow our trading & investment strategies, as they are subject to change without notice. Altitrade Partners has not received any form of  compensation in connection with the publication of this report.